



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bruno AMATI, et al.

Application No.: 10/625,486

Filed: July 22, 2003

For: METHODS OF MODULATING  
PROLIFERATIVE CONDITIONS

Examiner: Unknown

Art Unit: Unknown

Conf. No.: Unknown

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 19, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

by:

  
MELANIE LYONS

**INFORMATION DISCLOSURE STATEMENT**

Sir:

The materials as listed in the attached Form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB/08 listing references AA-BU.


Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached Form PTO/SB/08. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe that no fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.


Respectfully submitted,

Date: November 19, 2003

By:   
Sheela Mohan-Peterson  
Registration No.: 41,201  
Attorney for Applicants

***Customer No. 28008***

DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200



PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/625,486	
	Filing Date	07/22/2003	
	First Named Inventor	Bruno AMATI	
	Art Unit	Unknown	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	7*	Attorney Docket Number	DX01551K

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<b>Other Enclosures/Remarks:</b>	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<ul style="list-style-type: none"><li>• Form PTO/SB/08</li><li>• copies of cited references (AA thru BU)</li><li>• return receipt postcard</li></ul>	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	(* cited references are not included in the page count)	

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**


Firm or Individual	Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104
Signature	
Date	19-Nov-2003

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:			
Typed or printed	MELANIE LYONS		
Signature		Date	11-19-03

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/625,486
				Filing Date	July 22, 2003
				First Named Inventor	Bruno AMATI
				Art Unit	
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	DX01551K

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	ABDEL-GHANY, et al., "The breast cancer $\beta 4$ integrin and endothelial human CLCA2 mediate lung metastasis," J. Biol. Chem. 276(27)25438-25446 (July 6, 2001).	
	AB	AMATI, et al., "Function of the c-Myc oncoprotein in chromatin remodeling and transcription," Biochem. Biophys. Acta 1471:M135-M145 (2001)	
	AC	ASSELDONK, et al., "Construction of a 350-kb sequence-ready 11q13 cosmid contig encompassing the markers D11S4933 and D11S546," Genomics 66:35-42 (May 15 2000).	
	AD	BEIER, et al., "Induction of cyclin E-cdk2 kinase activity," EMBO J. 19(21)5813-5823 (November 2000).	
	AE	BEKRI, et al., "Detailed map of a region commonly amplified at 11q13 $\rightarrow$ q14 in human breast carcinoma," Cytogenet. Cell Genet. 79:125-131 (1997).	
	AF	BOYD, et al., "c-Myc target gene specificity is determined by post-DNA-binding mechanism," Proc. Natl. Acad. Sci. USA 95:13887-13892 (November 1998).	
	AG	BOYD, et al., "Myc versus USF," Mol. Cell. Biol. 17(5)2529-2537 (May 1997).	
	AH	BUSTIN, et al., "Expression of the Ca <sup>2+</sup> -activated chloride channel genes CLCA1 and CLCA2 is down regulated in human colorectal cancer," DNA and Cell Biol. (November 6, 2001).	
	AI	CHIEN, et al., "Response of alkalization or acidification by phytohemagglutinin is dependent on the activity of protein kinase C in human peripheral T cells," J. Cellular Biochem. 81:604-612 (2001).	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/625,486
				Filing Date	July 22, 2003
				First Named Inventor	Bruno AMATI
				Art Unit	
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	DX01551K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AJ	COLLER, et al., "Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion," Proc. Natl. Acad. Sci. USA 97:3260-3265 (March 28, 2000).	
	AK	DANG, "c-Myc target genes involved in cell growth, apoptosis, and metabolism," Mol. Cell. Biol. 19(1)1-11 (January 1999).	
	AL	DUHADAWAY, et al., "Bin1 mediates apoptosis by c-Myc in transformed primary cells," Cancer Res. 61:3151-3156 (April 1, 2001).	
	AM	EBERHARDY, et al., "c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism," J. Biol. Chem. 276(51)485-62-48571 (December 21, 2001).	
	AN	EBERHARDY, et al., "Direct examination of histone acetylation on Myc target genes using chromatin immunoprecipitation," J. Biol. Chem. 27(43)33798-33805 (October 27, 2000).	
	AO	ELBLE, et al., "Tumor suppression by a proapoptotic calcium-activated chloride channel in mammary epithelium," J. Biol. Chem. 276(2)40510-40517 (November 2, 2001).	
	AP	EMMA, et al., "Effect of cell swelling on membrane and cytoplasmic distribution of pI <sub>Cl<sub>m</sub></sub> ," Am. J. Physiol. 274:C1545-C1551 (1998).	
	AQ	FORCET, et al., "Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation," Nature 417:443-447 (May 23, 2002).	
	AR	FRANK, et al., "Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation," Genes Development 15:2069-2082 (2001).	
	AS	GAUGHAN, et al., "The human and mouse methylenetetrahydrofolate reductase (MTHFR) genes," Gene 257:279-289 (2000).	
	AT	GREASLEY, et al., "Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis," Nucleic Acids Res 28:446-453 (2000).	
	AU	GUTHRIE, "Axon guidance:netrin receptors are revealed," Current Biology 7:R6-R9 (1997).	
	AV	KARET, et al., "Localization of a gene for autosomal recessive distal renal tubular acidosis with normal hearing (rdRTA2) to 7q33-34," Am. J. Hum. Genet. 65:1656-1665 (1999).	
	AW	KORNAK, et al., "Complete genomic structure of the CLCN6 and CLCN7 putative chloride channel genes," Biochim. Biophys. Acta 1447:100-106 (1999).	
	AX	KATO, et al., "Identification and characterization of the human protein kinase-like gene NTKL," Genomics 79(6)760-767 (June 2002).	
	AY	KRAPIVINSKY, et al., "pI <sub>Cl<sub>m</sub></sub> binds to a mammalian homolog of a yeast protein involved in regulation of cell morphology," J. Biol. Chem. 273(18)10811-10814 (1998).	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/625,486
				Filing Date	July 22, 2003
				First Named Inventor	Bruno AMATI
				Art Unit	
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	DX01551K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AZ	LECANDA, et al., "Molecular cloning and genomic organization of the mouse AE2 anion exchanger gene," Biochem. Biophys. Res. Commun. 276:117-124 (2000).	
	BA	LEVENS, "Disentagling the Myc web," Proc. Natl. Acad. Sci. USA 99:5757-5759 (April 30, 2002).	
	BB	LIAO, et al., "c-Myc in breast cancer," Endocrine-Related Cancer 7:143-164 (2000).	
	BC	LIU, et al., "Cloning and preliminary characterization of a 105 kDa protein with an N-terminal kinase-like domain," Biochim. Biophys. Acta 1517:148-152 (2000).	
	BD	LIVESEY, et al., "Netrin and netrin receptor expression in the embryonic mammalian nervous system suggests roles in retinal, striatal, nigral, and cerebellar development," Molecular Cellular Neuroscience 8:417-429 (1997).	
	BE	LIVESEY, "Netrins and netrin receptors," Cell. Mol. Life Sci. 56:62-68 (1999).	
	BF	MEDINA, et al., "Molecular cloning and characterization of the human AE2 anion exchanger (SLC4A2) gene," Genomics 39:74-85 (1997).	
	BG	MEDINA, et al., "Tissue-specific N-terminal isoforms from overlapping alternate promoters of the human AE2 anion exchange gene," Biochem. Biophys. Res. Commun. 267:228-235 (2000).	
	BH	NAGL, et al., "Chromosomal localization of the genes (CLNS1A and CLNS1B) coding for the swelling-dependent chloride channel I <sub>cln</sub> ," Genomics 38:438-441 (1996).	
	BI	NESBIT, et al., "Myc oncogenes and human neoplastic disease," Oncogene 18:3004-3016 (1999).	
	BJ	OSTER, et al., "The Myc oncogene: marvelously complex," Adv. Cancer Res. 84:81-154 (2002).	
	BK	RAAY, et al., "The NTN2L gene encoding a novel human netrin maps to the autosomal dominant polycystic kidney disease region on chromosome 16p13.3," Genomics 41:279-282 (1997).	
	BL	RANSOM, et al., "Volume-activated chloride currents contribute to the resting conductance and invasive migration of human glioma cells," J. Neuroscience 21(19):7674-7683 (October 1, 2001).	
	BM	RESHKIN, et al., "Na <sup>+</sup> H <sup>+</sup> exchanger-dependent intracellular alkalization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes," FASEB J. 14:2185-2197 (2000).	
	BN	SAWYERS, "Rational therapeutic intervention in cancer: kinases as drug targets," Current Opinion Genetics Development 12:111-115 (2002).	
	BO	SCANDELLA, et al., "The promoter for constitutive expression of the human ICln gene CLNS1A," J. Biol. Chem. 275(21):15613-15620 (May 26, 2000).	
	BP	SOROCEAUNU, et al., "Modulation of glioma cell migration and invasion using Cl <sup>-</sup> and K <sup>+</sup> ion channel blockers," J. Neuroscience 19(14):5942-5954 (July 15, 1999).	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/625,486
				Filing Date	July 22, 2003
				First Named Inventor	Bruno AMATI
				Art Unit	
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	DX01551K

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	BQ	STRATOWA, et al., "A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity," Anti-Cancer Drug Design 14:393-402 (1999).		
	BR	SZABO, et al., "Tyrosine kinase-dependent activation of a chloride channel in CD95-induced apoptosis in T lymphocytes," Proc. Natl. Acad. Sci. USA 95:6169-6174 (May 1998).		
	BS	WANG, et al., "Netrin-3, a mouse homolog of human NTN2L, is highly expressed in sensory ganglia and shows differential binding to netrin receptors," J. Neuroscience 19(12)4938-4947 (June 15, 1999).		
	BT	WANG, et al., "Regulatory volume decrease is actively modulated during the cell cycle," J. Cellular Physiol. 193:110-119 (October 2002).		
	BU	WEINMANN, et al., "Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis," Genes Development 16:235-244 (January 15, 2002).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-1800-786-9199) and select option 2.